Windlas lifts dividend to ₹6.30 as profit rises 9% in FY26
Revenue grew 19% to ₹9,041M; profit touched ₹664M. Both numbers were in line with expectations.
— 3 earlier stories on Windlas Biotech Ltd. →Mkt cap₹1,773 cr
P/E26.67×
ROE12.06%
Debt / eq.0.05
Div yld0.73%
₹6.30 per share Dividend recommended (126% of face value)
What's new
- Dividend raised to ₹6.30 vs ₹5 last year.
- Revenue up 19% YoY, net profit up 9%.
- Results were widely anticipated; no surprises.
Why this matters
The dividend increase signals confidence, but the results were already priced in after prior guidance and buyback. For a micro-cap pharma, steady execution is expected; this filing doesn't alter the thesis.
What we're watching
- Next quarter's revenue trajectory.
- Any signal on capex or new product launches.
- Whether the buyback completion affects float.
The full read
Windlas posted predictable numbers for FY26—₹9,041M revenue, ₹664M profit—in line with guided expectations. The dividend bump to ₹6.30 is a small positive but not a surprise. With no deviation from anticipated performance, the filing confirms the existing narrative without adding trading torque.
Mentioned: ₹6.30 dividend · FY26 revenue ₹9,041M · net profit ₹664M
Company snapshot
Windlas Biotech Ltd.
Pharmaceuticals
₹1,650 cr
P/E 24.73×
Latest quarter · Mar 2026
Sales₹238 cr
Net profit₹16 cr
Op. margin+10.6%
EPS₹7.58
Strength & growth
Debt / equity0.05×
Current ratio2.11×
Story so far
All notes on WINDLAS →- 21 May 2026 · 4:54 PM IST Windlas lifts dividend to ₹6.30 as profit rises 9% in FY26
- 51d ago Windlas Biotech misses Plant 6 timeline as regulatory hit cuts revenue
- 52d ago Windlas Biotech’s ₹904 Cr revenue: record, but already priced in.
- 52d ago Windlas Biotech meets FY26 estimates; dividend raised to ₹6.30